Join Legend Biotech for a virtual KOL event featuring Leyla Shune, MD (Franciscan Health) and Marco Davila, MD, PhD (Roswell Park Comprehensive Cancer Center), who will join company management to discuss CARVYKTI for the treatment of relapsed or refractory multiple myeloma (RRMM).

The event will provide an overview of the latest CARVYKTI data from Legend’s poster presentations at the International Myeloma Society (IMS) Annual Meeting. CARVYKTI is the first CAR-T therapy for multiple myeloma approved after one other treatment has not worked or has stopped working, given as a one-time infusion. Management will review the five-year follow-up CARTITUDE-2 Cohort A data, a Phase 2 study cohort evaluating ciltacabtagene autoleucel (cilta-cel) in patients with RRMM who had received 1-3 prior lines of therapy, real world outcome data from the eMMpower-CART study, and first results from a noninterventional, prospective post-authorization safety study in RRMM.

A live question and answer session will follow the formal presentations.